Clinical trials: Botulinum Toxin
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
- Trial name
- NCT00311376
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 416 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
- Trial name
- NCT00461292
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 12 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Allergan
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS I (NCT02677298)
- Testing
- Botulinum Toxin A
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the efficacy and safety of a single administration of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal lines.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968825
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as…
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01064518
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
This study is a phase 3 clinical trial of multi-center, random, blinded*, parallel control, and positive control to evaluate the efficacy and safety of Botulax® Injection compared to BOTOX® for improving moderate to severe…
- Trial name
- NCT05380154
- Testing
- Botulinum Toxin A type for injection (Botulax®), Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Hugel
Glabellar Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of…
- Trial name
- NCT02493946
- Testing
- Botulinum toxin type A
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 600 people
- Sponsor
- Ipsen
Wrinkles
Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines
The dermatological treatment for reducing facial wrinkles with injectable drug Botulift (botulinum toxin type A - Laboratório Químico Farmacêutico BergamoLtd.) has a not inferior activity when compared with Botox ® (botulinum…
- Trial name
- NCT01180348
- Testing
- Botulift, Botox
- Where
- Brazil
- Volunteers
- 192 people
- Sponsor
- Azidus Brasil
Low Back Pain
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients…
- Trial name
- NCT00246155
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ipsen
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Upper Limb Spasticity
Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice
The primary purpose for this study is to understand the effect of botulinum toxin as a treatment integrated in the management of spasticity (stiffness) in the arm and/or hand, arising from any neurological condition.
- Trial name
- ULIS III (NCT02454803)
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 1,004 people
- Sponsor
- Ipsen
Cerebrovascular Accident
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare Botulinum Toxin Type A for Injection (HengLi®) with placebo on the efficacy and safety of treatment in post-stroke subjects with focal…
- Trial name
- NCT02280083
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 180 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Urinary Incontinence, Urinary Bladder, Overactive
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder…
- Trial name
- NCT02010788
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Allergan
Chronic Migraine
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
A study, multi-center, randomized, double-blind, placebo parallel-controlled method, will be carried out to evaluate the safety and efficacy of Botulinum Toxin Type A for injection (HengLi®) for prophylactic treatment with…
- Trial name
- NCT02291380
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 288 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Migraine Disorders
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.
- Trial name
- NCT03193346
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Forehead Lines
A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants
Facial lines (such as glabellar lines [GL], lateral canthal lines [LCL], and forehead lines [FHL]) are perhaps the most visible signs of aging.
- Trial name
- NCT06174688
- Testing
- BOTOX
- Where
- 12 sites in China
- Volunteers
- 140 people
- Sponsor
- AbbVie
Habitual Snoring
Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring
The purpose of this study is to identify out of up to three doses a safe and effective dose of Botulinum toxin type A for an injection into one side of the soft palate to treat snoring.
- Trial name
- NCT01515371
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Healthy Volunteers
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
The primary purpose of this study is: 1. To evaluate the model determined by the ability of botulism antitoxin (bivalent, Aventis) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage…
- Trial name
- NCT00636519
- Testing
- Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions